» Articles » PMID: 23360980

MEK-1 Activates C-Raf Through a Ras-independent Mechanism

Overview
Specialties Biochemistry
Biophysics
Date 2013 Jan 31
PMID 23360980
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

C-Raf is a member of the Ras-Raf-MEK-ERK mitogen-activated protein kinase (MAPK) signaling pathway that plays key roles in diverse physiological processes and is upregulated in many human cancers. C-Raf activation involves binding to Ras, increased phosphorylation and interactions with co-factors. Here, we describe a Ras-independent in vivo pathway for C-Raf activation by its downstream target MEK. Using (32)P-metabolic labeling and 2D-phosphopeptide mapping experiments, we show that MEK increases C-Raf phosphorylation by up-to 10-fold. This increase was associated with C-Raf kinase activation, matching the activity seen with growth factor stimulation. Consequently, coexpression of wildtype C-Raf and MEK was sufficient for full and constitutive activation of ERK. Notably, the ability of MEK to activate C-Raf was completely Ras independent, since mutants impaired in Ras binding that are irresponsive to growth factors or Ras were fully activated by MEK. The ability of MEK to activate C-Raf was only partially dependent on MEK kinase activity but required MEK binding to C-Raf, suggesting that the binding results in a conformational change that increases C-Raf susceptibility to phosphorylation and activation or in the stabilization of the phosphorylated-active form. These findings propose a novel Ras-independent mechanism for activating the C-Raf and the MAPK pathway without the need for mutations in the pathway. This mechanism could be of significance in pathological conditions or cancers overexpressing C-Raf and MEK or in conditions where C-Raf-MEK interaction is enhanced due to the down-regulation of RKIP and MST2.

Citing Articles

Drug resistance in targeted cancer therapies with RAF inhibitors.

Degirmenci U, Yap J, Sim Y, Qin S, Hu J Cancer Drug Resist. 2022; 4(3):665-683.

PMID: 35582307 PMC: 9094075. DOI: 10.20517/cdr.2021.36.


Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway.

Zhao J, Luo Z Int J Mol Sci. 2022; 23(9).

PMID: 35563547 PMC: 9101324. DOI: 10.3390/ijms23095158.


Dissecting the novel partners of nuclear c-Raf and its role in all-trans retinoic acid (ATRA)-induced myeloblastic leukemia cells differentiation.

Rashid A, Wang R, Zhang L, Yue J, Yang M, Yen A Exp Cell Res. 2020; 394(1):111989.

PMID: 32283065 PMC: 10656057. DOI: 10.1016/j.yexcr.2020.111989.


Metabolic stress regulates ERK activity by controlling KSR-RAF heterodimerization.

Verlande A, Krafcikova M, Potesil D, Trantirek L, Zdrahal Z, Elkalaf M EMBO Rep. 2017; 19(2):320-336.

PMID: 29263201 PMC: 5797961. DOI: 10.15252/embr.201744524.


Families of microRNAs Expressed in Clusters Regulate Cell Signaling in Cervical Cancer.

Servin-Gonzalez L, Granados-Lopez A, Lopez J Int J Mol Sci. 2015; 16(6):12773-90.

PMID: 26057746 PMC: 4490472. DOI: 10.3390/ijms160612773.


References
1.
Udell C, Rajakulendran T, Sicheri F, Therrien M . Mechanistic principles of RAF kinase signaling. Cell Mol Life Sci. 2010; 68(4):553-65. PMC: 11114552. DOI: 10.1007/s00018-010-0520-6. View

2.
King A, Sun H, Diaz B, Barnard D, Miao W, Bagrodia S . The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature. 1998; 396(6707):180-3. DOI: 10.1038/24184. View

3.
Takekawa M, Tatebayashi K, Saito H . Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell. 2005; 18(3):295-306. DOI: 10.1016/j.molcel.2005.04.001. View

4.
Kyriakis J, App H, Zhang X, Banerjee P, Brautigan D, Rapp U . Raf-1 activates MAP kinase-kinase. Nature. 1992; 358(6385):417-21. DOI: 10.1038/358417a0. View

5.
Kaplan F, Shao Y, Mayberry M, Aplin A . Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene. 2010; 30(3):366-71. PMC: 6591715. DOI: 10.1038/onc.2010.408. View